Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
McKinsey
Colorcon
McKesson
Dow

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,153,653

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,153,653
Title: Choline compositions and uses thereof
Abstract:The invention provides compositions that include conjugates of choline and a fatty acid, preferably cis-docosahexaenoic acid. The conjugates are useful in treating disorders resulting from cerebral ischemia including stroke.
Inventor(s): Shashoua; Victor E. (Belmont, MA)
Assignee: Protarga, Inc. (Conshohocken, PA)
Application Number:08/979,313
Patent Claims:1. A method for treating stroke comprising:

administering to a subject who has experienced a stroke an amount of a covalent conjugate of choline and a fatty acid having 12-26 carbons in an amount effective to treat stroke.

2. The method of claim 1, wherein the fatty acid is an unbranched, naturally occurring fatty acid.

3. The method of claim 2, wherein the fatty acid has 14-22 carbons.

4. The method of claim 1, wherein the fatty acid is conjugated to choline via an ester bond between the COOH of the fatty acid and the OH of choline.

5. The method of claim 1, wherein the covalent conjugate is ##STR6##

6. The method of claims 1, 2, 3, 4 or 5 further comprising administering to the subject an anti-stroke agent other than the covalent conjugate.

7. The method of claim 6 wherein the anti-stroke agent is selected from the group consisting of antiplatelet agents, anticoagulation agents, thrombolytic agents including plasminogen activators, antithrombotics, neuroprotective agents, platelet activating factor antagonists, platelet aggregation inhibitors, post-stroke and post-head trauma agents, cerebral ischemia agents, basic fibroblast growth factors and steroids.

8. The method of claim 7 wherein the anti-stroke agent is selected from the group consisting of citicholine, dizocilpine, alteplase, urokinase, and lexipafant.

9. A method for protecting cortical cells from ischemia-induced cell death comprising contacting the cortical cells which have been exposed to ischemic conditions sufficient to induce cell death with a covalent conjugate of choline and a fatty acid having 12-26 carbons in an amount effective to protect the cortical cells against cell death which would otherwise result from the ischemic conditions.

10. The method of claim 9, wherein the fatty acid is an unbranched, naturally occurring fatty acid.

11. The method of claim 10, wherein the fatty acid has 14-22 carbons.

12. The method of claim 9, wherein the fatty acid is conjugated to choline via an ester bond between the COOH of the fatty acid and the OH of choline.

13. The method of claim 9, wherein the covalent conjugate is ##STR7##

14. A method for selectively protecting cortical cells of a subject from stroke-induced cell death comprising: administering to a subject who has experienced a stroke a covalent conjugate of choline and a fatty acid having 12-26 carbons in an amount effective to protect the cortical cells from stroke-induced cell death.

15. The method of claim 14, wherein the fatty acid is an unbranched, naturally occurring fatty acid.

16. The method of claim 15, wherein the fatty acid has 14-22 carbons.

17. The method of claim 14, wherein the fatty acid is conjugated to choline via an ester bond between the COOH of the fatty acid and the OH of choline.

18. The method of claim 14, wherein the covalent conjugate is ##STR8##

Details for Patent 6,153,653

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 001 1987-11-13   Start Trial Protarga, Inc. (Conshohocken, PA) 2036-04-30 RX search
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 002 1987-11-13   Start Trial Protarga, Inc. (Conshohocken, PA) 2036-04-30 RX search
Genentech CATHFLO ACTIVASE alteplase VIAL 103172 003 1987-11-13   Start Trial Protarga, Inc. (Conshohocken, PA) 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Moodys
McKesson
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.